Evolus, Inc., a performance beauty company, provides medical aesthetic products for physicians and their patients in the United States. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. The company was founded in 2012 and is headquartered in Newport Beach, California.
IPO Year: 2018
Exchange: NASDAQ
Website: evolus.com
Date | Price Target | Rating | Analyst |
---|---|---|---|
1/29/2024 | $10.00 → $16.00 | Equal Weight → Overweight | Barclays |
6/23/2022 | $18.00 | Buy | Needham |
5/12/2022 | $8.00 → $10.00 | Underweight → Equal Weight | Barclays |
1/20/2022 | $11.00 | Hold → Buy | Truist |
11/3/2021 | $22.00 → $15.00 | Buy | HC Wainwright & Co. |
Evolus, Inc. (NASDAQ:EOLS), a performance beauty company with a focus on building an aesthetic portfolio, today announced the company will be ringing the Nasdaq closing bell on Friday, September 13, 2024. The Nasdaq closing bell ceremony is a time-honored tradition, serving as a platform for companies to celebrate achievements and milestones. The Nasdaq closing bell ceremony will take place at the Nasdaq MarketSite in Times Square, New York City. David Moatazedi, Evolus' President and Chief Executive Officer, will preside over the ceremony, joined by members of the company's leadership team and guests. Evolus' President and Chief Executive Officer, David Moatazedi, commented, "We are ho
Evolus, Inc. (NASDAQ:EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today reported the grant in July an aggregate of 46,363 restricted stock units (RSUs) of the company's common stock to 16 newly hired non-executive employees of the company (the "July Grants"). The Company also is reporting the grant in August of an aggregate of 35,921 RSUs and non-qualified stock options to purchase an aggregate of 18,097 shares of Evolus to 10 newly hired non-executive employees of the Company (the "August Grants"). The awards were approved by the compensation committee of the company's board of directors under the Evolus' 2023 Inducement Incentive
Total Net Revenue of $66.9 Million for Q2 2024, Up 36% from Q2 2023 Raises Full-Year 2024 Net Revenue Guidance to $260 Million to $270 Million, Representing Year-Over-Year Growth of 34% at the Top End Improved Quarterly GAAP Operating Loss to $7.7 Million; Delivered First Ever Quarter of Profitability1 with Positive Non-GAAP Operating Income of $1.1 Million for Q2 2024 Premarket Approval (PMA) Application Submitted to the U.S. Food and Drug Administration (FDA) for Evolysse™ Lift and Evolysse™ Smooth Fillers, Approval and Launch Expected in Second Half of 2025 Evolus, Inc. (NASDAQ:EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer br
Evolus, Inc. (NASDAQ:EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that it will host an Investor Day on Thursday, September 12, 2024 in New York City. Attendees can join in-person or participate via webcast. The event will be hosted at the "SECOND Floor" venue located at 849 6th Ave, New York, NY 10001. The event will begin at 7:30 a.m. ET with breakfast, followed by formal presentations starting at 8:00 a.m. ET, with the webcast portion of the event concluding by approximately 12:00 p.m. ET. During the event, Evolus' management team will provide in-depth presentations and discussions of the Company's strategic vi
Launching into this growth market1 as part of the company's geographic expansion strategy Evolus Australia established to drive medical education, training, marketing and sales to medical aesthetics healthcare professionals Evolus, Inc. (NASDAQ:EOLS), a performance beauty company focused on building an aesthetic portfolio, has commenced operations in Australia with the launch of Nuceiva® (prabotulinumtoxinA). Nuceiva® is approved by the Therapeutic Goods Administration (TGA) for the temporary improvement in the appearance of moderate to severe glabellar lines in adult patients2. "Launching Evolus in Australia underscores our commitment to strategic geographic expansion and our de
Evolus, Inc. (NASDAQ:EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that Sandra Beaver, CFO, will present at the following investor conference. Event: The Canaccord Genuity 44th Annual Growth Conference Date: Tuesday, August 13, 2024 Time: 12:30 – 12:55 PM ET The fireside chat can be accessed on the Investor Relations page of the Evolus website here. A replay of the webcast will be available for 90 days following the presentation. About Evolus, Inc. Evolus (NASDAQ:EOLS) is a global performance beauty company evolving the aesthetic neurotoxin market for the next generation of beauty consumers through its unique,
Evolus, Inc. (NASDAQ:EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that it will report its second quarter 2024 financial results on Wednesday, July 31, 2024, after the U.S. financial markets close. Evolus management will host a conference call and live webcast to discuss these results at 4:30 p.m. ET that same day. A question-and-answer session will follow management's remarks. To participate in the conference call, dial (877) 407-6184 (U.S.) or (201) 389-0877 (international) or connect live via webcast on the Investor Relations page of the Evolus website here. Following the completion of the call, a telephonic
Evolus, Inc. (NASDAQ:EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced the appointment of Albert G. White III, President and Chief Executive Officer of The Cooper Companies, Inc. to the Evolus Board of Directors, effective July 1. Mr. White will also serve as a member of Evolus' Compensation Committee. "We are pleased to welcome Al White to the Evolus Board," said Vik Malik, Chairman of the Board of Directors. "Al's extensive leadership experience, industry knowledge, and proven track record of building a leading medical technology company will be a valuable resource as Evolus embarks on a path from a single-product aes
Evolus, Inc. (NASDAQ:EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that it has submitted the final module of its premarket approval (PMA) application to the U.S. Food and Drug Administration (FDA) for the Evolysse™ Lift and Evolysse™ Smooth dermal filler products for the nasolabial fold (NLF). "We are pleased to have submitted the final module of the PMA application," said Dr. Rui Avelar, MD, Chief Medical Officer and Head of R&D. "This submission is a key fundamental milestone for Evolus and we look forward to our continued collaboration with the Agency in the upcoming thorough review process." Evolus anticipates
Launching in one of the five largest aesthetic toxin injectable markets in Europe1 as part of the company's geographic expansion strategy Evolus to provide Nuceiva® for direct order and delivery to Spanish medical aesthetics healthcare professionals Evolus, Inc. (NASDAQ:EOLS), a performance beauty company focused on building an aesthetic portfolio, has commercially launched Nuceiva® (botulinum toxin type A) in Spain. The product is now available for direct order and delivery to Spanish medical aesthetics healthcare professionals. Nuceiva® is approved by the European Commission for the temporary improvement in the appearance of moderate to severe vertical lines between the eyebrows
4 - Evolus, Inc. (0001570562) (Issuer)
4 - Evolus, Inc. (0001570562) (Issuer)
3 - Evolus, Inc. (0001570562) (Issuer)
4 - Evolus, Inc. (0001570562) (Issuer)
4 - Evolus, Inc. (0001570562) (Issuer)
4 - Evolus, Inc. (0001570562) (Issuer)
4 - Evolus, Inc. (0001570562) (Issuer)
4 - Evolus, Inc. (0001570562) (Issuer)
4 - Evolus, Inc. (0001570562) (Issuer)
4 - Evolus, Inc. (0001570562) (Issuer)
Evolus, Inc. (NASDAQ:EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that it has submitted the final module of its premarket approval (PMA) application to the U.S. Food and Drug Administration (FDA) for the Evolysse™ Lift and Evolysse™ Smooth dermal filler products for the nasolabial fold (NLF).
Cantor Fitzgerald analyst Louise Chen reiterates Evolus (NASDAQ:EOLS) with a Overweight.
Launching in one of the five largest aesthetic toxin injectable markets in Europe1 as part of the company's geographic expansion strategyEvolus to provide Nuceiva® for direct order and delivery to Spanish medical aesthetics healthcare professionalsEvolus, Inc. (NASDAQ:EOLS), a performance beauty company focused on building an aesthetic portfolio, has commercially launched Nuceiva® (botulinum toxin type A) in Spain. The product is now available for direct order and delivery to Spanish medical aesthetics healthcare professionals.
HC Wainwright & Co. analyst Douglas Tsao reiterates Evolus (NASDAQ:EOLS) with a Buy and maintains $27 price target.
HC Wainwright & Co. analyst Douglas Tsao reiterates Evolus (NASDAQ:EOLS) with a Buy and maintains $27 price target.
Needham analyst Serge Belanger reiterates Evolus (NASDAQ:EOLS) with a Buy and maintains $22 price target.
Evolus (NASDAQ:EOLS) reported quarterly losses of $(0.08) per share which beat the analyst consensus estimate of $(0.10) by 20 percent. This is a 46.67 percent increase over losses of $(0.15) per share from the same period last year. The company reported quarterly sales of $59.333 million which beat the analyst consensus estimate of $57.321 million by 3.51 percent. This is a 42.21 percent increase over sales of $41.721 million the same period last year.
The article published in Aesthetic Surgery Journal supports safety and duration of effect for temporary improvement in the appearance of moderate to severe glabellar lines presented at the 2023 ASDS Annual MeetingData showed duration effect of 26 weeks, or 6 months, based on a ≥ 1-point Glabellar Line Scale (GLS) improvement and return to baseline value using the Global Aesthetic Improvement ScaleEvolus, Inc. (NASDAQ:EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that the Aesthetic Surgery Journal has published the safety and duration of effect results from the Phase 2 study of 40U Jeuveau® (prabotulinumtoxinA-xvfs) for
Needham analyst Serge Belanger reiterates Evolus (NASDAQ:EOLS) with a Buy and maintains $22 price target.
SC 13G - Evolus, Inc. (0001570562) (Subject)
SC 13G/A - Evolus, Inc. (0001570562) (Subject)
SC 13G/A - Evolus, Inc. (0001570562) (Subject)
SC 13G - Evolus, Inc. (0001570562) (Subject)
SC 13G/A - Evolus, Inc. (0001570562) (Subject)
SC 13G/A - Evolus, Inc. (0001570562) (Subject)
SC 13G - Evolus, Inc. (0001570562) (Subject)
SC 13G - Evolus, Inc. (0001570562) (Subject)
SC 13G/A - Evolus, Inc. (0001570562) (Subject)
SC 13G/A - Evolus, Inc. (0001570562) (Subject)
Barclays upgraded Evolus from Equal Weight to Overweight and set a new price target of $16.00 from $10.00 previously
Needham initiated coverage of Evolus with a rating of Buy and set a new price target of $18.00
Barclays upgraded Evolus from Underweight to Equal Weight and set a new price target of $10.00 from $8.00 previously
Truist upgraded Evolus from Hold to Buy and set a new price target of $11.00
HC Wainwright & Co. reiterated coverage of Evolus with a rating of Buy and set a new price target of $15.00 from $22.00 previously
Barclays reiterated coverage of Evolus with a rating of Underweight and set a new price target of $7.00 from $8.00 previously
Mizuho upgraded Evolus from Neutral to Buy and set a new price target of $15.00
HC Wainwright & Co. reiterated coverage of Evolus with a rating of Buy and set a new price target of $22.00 from $20.00 previously
HC Wainwright & Co. reiterated coverage of Evolus with a rating of Buy and set a new price target of $20.00 from $18.00 previously
HC Wainwright reiterated coverage of Evolus with a rating of Buy and set a new price target of $18.00 from $6.00 previously
10-Q - Evolus, Inc. (0001570562) (Filer)
8-K - Evolus, Inc. (0001570562) (Filer)
8-K - Evolus, Inc. (0001570562) (Filer)
8-K - Evolus, Inc. (0001570562) (Filer)
144 - Evolus, Inc. (0001570562) (Subject)
10-Q - Evolus, Inc. (0001570562) (Filer)
8-K - Evolus, Inc. (0001570562) (Filer)
DEFA14A - Evolus, Inc. (0001570562) (Filer)
DEF 14A - Evolus, Inc. (0001570562) (Filer)
ARS - Evolus, Inc. (0001570562) (Filer)
Evolus, Inc. (NASDAQ:EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced the appointment of Albert G. White III, President and Chief Executive Officer of The Cooper Companies, Inc. to the Evolus Board of Directors, effective July 1. Mr. White will also serve as a member of Evolus' Compensation Committee. "We are pleased to welcome Al White to the Evolus Board," said Vik Malik, Chairman of the Board of Directors. "Al's extensive leadership experience, industry knowledge, and proven track record of building a leading medical technology company will be a valuable resource as Evolus embarks on a path from a single-product aes
Evolus, Inc. (NASDAQ:EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that Nareg Sagherian has joined the Company as Vice President, Head of Global Investor Relations and Corporate Communications. In this role, Nareg will be responsible for interacting with current and prospective investors and managing a strategic investor relations and corporate communications program. Nareg will report to Sandra Beaver, Chief Financial Officer of Evolus. "I am thrilled to welcome Nareg to our team," said Sandra Beaver, Chief Financial Officer of Evolus. "Nareg's unique experience will enable him to drive a successful investor relati
Industry Leader Brings 20+ Years of Cosmetic Expertise to the Performance Beauty Category Evolus, Inc. (NASDAQ:EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, has named Ms. Tomoko Yamagishi-Dressler as Chief Marketing Officer (CMO), effective today. Yamagishi-Dressler is an accomplished executive with more than two decades of established excellence leading omnichannel marketing for global beauty companies. A true strategist, Yamagishi-Dressler has successfully driven profitable business growth and increased equity for an iconic portfolio of industry brands. This press release features multimedia. View the full release here: https:
Evolus, Inc. (NASDAQ:EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, has named Sandra Beaver as its Chief Financial Officer, effective September 5, 2022. Ms. Beaver brings more than 20 years of financial experience, driving company growth through strategic planning, long-range forecasting, executing corporate development and capital markets transactions, and improving operational efficiency. Most recently, Ms. Beaver served as Senior Vice President of Finance at Experian, where she was responsible for consolidated financial planning & analysis for half of the company's North America B2B business units with revenue in excess
Evolus, Inc. (NASDAQ:EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, today announced that after nearly four years with the company, Lauren Silvernail will retire from her position as Chief Financial Officer and Executive Vice President of Corporate Development effective May 31, 2022. The search for her successor is already underway. "Lauren has had an incredible impact on this company, and we are grateful for her many contributions to Evolus," said David Moatazedi, President and CEO at Evolus. "Lauren has been instrumental in helping us build this company from a development stage organization to a fast-growing and well-funde
Evolus, Inc. (NASDAQ:EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, today announced that it has further strengthened and diversified its Board of Directors with the appointment of digital and beauty innovator Brady Stewart. "On behalf of my fellow Board members and the Evolus management team, I am pleased to welcome Brady to our Board of Directors," said Vikram Malik, Chairman. "Brady's wealth of experience in digital innovation, the beauty industry and direct-to-consumer advertising will be a valuable resource as Evolus embarks on a path to become a leading, multi-product aesthetics company." With over 20 years of experie
Tenaya Therapeutics, Inc. (NASDAQ:TNYA), a biotechnology company with a mission to discover, develop and deliver curative therapies that address the underlying causes of heart disease, today announced the appointments of Karah Parschauer, J.D., to its Board of Directors and of Joanna Auch as Senior Vice President of People and Culture. "Tenaya is at an important inflection point in our growth and maturity. We are now a public company with more than 100 employees who represent our commitment to internalize critical capabilities, including cGMP manufacturing and clinical development," said Faraz Ali, CEO of Tenaya. "Both Karah and Joanna are strong leaders who bring highly relevant strategic
NEWPORT BEACH, Calif., Nov. 01, 2021 (GLOBE NEWSWIRE) -- Evolus, Inc. (NASDAQ:EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, today announced that Jessica Novak, SPHR has joined the company as Senior Vice President, Human Resources where she will oversee global efforts to expand, retain and develop an entrepreneurial team bringing innovative products and marketing solutions to the aesthetics industry. "One of Evolus' greatest assets is our people who are energized by our company's mission to make the beauty experience delightful and achievable," said David Moatazedi, Evolus' President and Chief Executive Officer. "Jessica's
NEWPORT BEACH, Calif., June 30, 2021 (GLOBE NEWSWIRE) -- Evolus, Inc. (NASDAQ:EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, today announced that David K. Erickson has joined the company as Vice President, Investor Relations where he will be responsible for developing, implementing and managing a comprehensive and strategic investor relations program. "David brings more than 25 years of investor relations and healthcare industry experience to this position, which will benefit Evolus as we continue to grow our global footprint, including our European launch expected in early 2022," said Lauren Silvernail, Evolus' Chief Fi
NEWPORT BEACH, Calif., May 19, 2021 (GLOBE NEWSWIRE) -- Evolus, Inc. (NASDAQ:EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, today announced the appointment of Dan Stewart as Vice President and General Manager of the company's International business. "Dan has an extensive track record of success and a global reputation built from 20 years of experience in aesthetics," said Crystal Muilenburg, Chief Marketing Officer. "We look forward to Dan leading the expansion of Evolus' global footprint starting with the launch of Nuceiva™ in Europe in early 2022." Dan is a seasoned operational leader with more than 20 years of experien
Evolus, Inc. (NASDAQ:EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that it will report its second quarter 2024 financial results on Wednesday, July 31, 2024, after the U.S. financial markets close. Evolus management will host a conference call and live webcast to discuss these results at 4:30 p.m. ET that same day. A question-and-answer session will follow management's remarks. To participate in the conference call, dial (877) 407-6184 (U.S.) or (201) 389-0877 (international) or connect live via webcast on the Investor Relations page of the Evolus website here. Following the completion of the call, a telephonic
Q1 2024 Net Revenue of $59.3 Million, Up 42% from Q1 2023 Non-GAAP Loss from Operations of $0.9 Million, on Track to Non-GAAP Profitability1 in Q4 2024 and Full Year 2025 U.S. Clinical Trials Completed for Evolysse® Lift and Smooth fillers, FDA Submission Expected within Next 90 Days Reaffirms Full-Year 2024 Net Revenue Guidance of $255 Million to $265 Million, Representing a 31% Growth Rate at the Top End Remains on Track to Achieve Projected Total Net Revenue Goal of At Least $700 Million by 2028 Evolus, Inc. (NASDAQ:EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today reported financial results for the first quarter
Evolus, Inc. (NASDAQ:EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that it will report its first quarter 2024 financial results on Tuesday, May 7, 2024, after the U.S. financial markets close. Evolus management will host a conference call and live webcast to discuss these results at 4:30 p.m. ET that same day. A question-and-answer session will follow management's remarks. To participate in the conference call, dial (877) 407-6184 (U.S.) or (201) 389-0877 (international) or connect live via webcast on the Investor Relations page of the Evolus website here. Following the completion of the call, a telephonic repla
Generated $0.8M of Cash from Operating Activities in Q4 2023 Recorded Lowest Quarter of Non-GAAP Operating Loss Since Inception, Non-GAAP Operating Loss for Q4 is $3.7 Million, an Improvement of $2 Million Compared to Q3 Full Year 2023 Operating Expense of $163.9 Million in Alignment with Guidance Range of $160 Million to $165 Million Global Net Revenue Record of $61.0 Million for the Fourth Quarter and $202.1 Million Full Year 2023, Representing 40% and 36% Growth Over the Prior Year; These Results Are Unchanged from the Preliminary Results Reported on January 16th, 2024 Company Updates Mid-Term Guidance and Expects to Achieve Profitability1 for the Fourth Quarter of 2024 an
Evolus dermal filler product (Evolysse™/Estyme® Lift) demonstrates statistical superiority at 3 and 6 months compared to Restylane-L with respect to improvement in nasolabial fold severity The European Lift study met the primary endpoint of non-inferiority Evolus, Inc. (NASDAQ:EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that it will provide the data presented at IMCAS during its upcoming Earnings conference call on March 7th at 4:30 p.m. ET. Evolus remains on track for the global commercial launch of the first-generation Cold HA Technology in 2025. The filler line will be branded Evolysse™ in the US and Est
Evolus, Inc. (NASDAQ:EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that it will report its fourth quarter and year end 2023 financial results and provide a business update on Thursday, March 7, 2024, after the U.S. financial markets close. Evolus management will host a conference call and live webcast to discuss these results at 4:30 p.m. ET that same day. A question-and-answer session will follow management's remarks. To participate in the conference call, dial (877) 407-6184 (U.S.) or (201) 389-0877 (international) or connect live via webcast on the Investor Relations page of the Evolus website here. Following
Record Quarterly Net Revenue of $50 Million for Q3 2023, Up 48% from Q3 2022 Raises Full-Year 2023 Net Revenue Guidance from $185 to $195 Million to $194 to $198 Million Operating Use of Cash in Q3 of $0.9 Million, Demonstrating Continued Progress Towards Achieving Profitability1 with Existing Liquidity "Extra-Strength" 40U Formulation of Jeuveau® Demonstrates Effects Lasting 26 Weeks in Phase II Data Presented at 2023 American Society of Dermatologic Surgery Annual Meeting Evolus, Inc. (NASDAQ:EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today reported financial results for the third quarter ended September 30, 2023.
Evolus, Inc. (NASDAQ:EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that it will report its third quarter 2023 financial results and provide a business update on Tuesday, November 7, 2023, after the U.S. financial markets close. Evolus management will host a conference call and live webcast to discuss these results at 4:30 p.m. ET that same day. A question-and-answer session will follow management's remarks. To participate in the conference call, dial (877) 407-6184 (U.S.) or (201) 389-0877 (international) or connect to the live webcast via the link on the Investor Relations page of the Evolus website at www.evolus
Q2 2023 Net Revenue of $49.3 Million, Up 33% from Q2 2022 Raises Full-Year 2023 Net Revenue Guidance to $185 to $195 Million On Track to Achieving Sustained Profitability with Existing Cash Evolus, Inc. (NASDAQ:EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today reported financial results for the second quarter ended June 30, 2023 and provided a business update. "The results of our second quarter clearly demonstrate an acceleration of trends and consistent execution of our long-term growth strategy," said David Moatazedi, President and Chief Executive Officer. "With record quarterly revenue as well as all-time highs a
Company Increases Full-Year 2023 Net Revenue Guidance to $185 to $195 Million Company Achieved Quarterly Net Revenue of $49.3 Million, Growing 33% Year-over-Year and 10 Percentage Points Above the First Quarter's Growth Rate Achieved Record Growth and All-time Highs in New Accounts, and Consumer Loyalty Enrollments and Redemptions Evolus, Inc. (NASDAQ:EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today reported revenue for the second quarter ended June 30, 2023 and raised its revenue guidance for the full year. Net revenue for the second quarter of 2023 was $49.3 million, a 33% increase over the corresponding quarter in t